Armata Pharmaceuticals, Inc. - 8-K Filing
Armata Pharmaceuticals announced clinical and regulatory progress for AP-SA02 toward a planned Phase 3 study in complicated S. aureus bacteremia, along with $28.7 million total funding from the U.S. Department of Defense. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $ARMP